S11 Ep49: Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD
In today’s episode, supported by BeiGene, Alexey Danilov, MD, PhD, hosted a discussion with Susan M. O'Brien, MD, about key data updates with BTK inhibitors in patients with chronic lymphocytic leukemia (CLL) that were presented at the 2024 ASH Annual Meeting. Dr Danilov is the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, the medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, co-director of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma at the Department of Hematology & Hematopoietic Cell…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.